Amphipathic Opioid Antagonist Conjugate for Peripheral Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid receptor antagonists used to treat constipation induced by opioid analgesics often have adverse effects on the central nervous system and lack specificity, leading to unpredictable and non-targeted side effects, while existing methods for managing constipation are inadequate in reducing opioid-induced bowel disorders.
Innovation Solution
A hydrophilic polymer, such as polyethylene glycol, is covalently conjugated with opioid receptor antagonists like naltrexone to create a conjugate that preferentially targets peripheral opioid receptors, reducing central nervous system toxicity and maintaining analgesic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic opioid receptor antagonists are used to treat constipation, then peripheral opioid effects are blocked, but central analgesic effects are also attenuated causing CNS side effects
Solution Approach 1:
The patent applies local quality by making the opioid receptor antagonist amphipathic with a hydrophilic portion and a lipophilic portion. The lipophilic portion enables penetration into peripheral nerve membranes to block peripheral opioid receptors, while the hydrophilic portion prevents crossing of the blood-brain barrier, thereby achieving selective peripheral action without central nervous system side effects.
Solution Approach 2:
The amphipathic structure acts as an intermediary between the hydrophilic environment of blood plasma and the lipophilic environment of nerve membranes. The molecule's dual nature allows it to be transported in the bloodstream while selectively interacting with peripheral nerve membranes, serving as a mediator that achieves peripheral selectivity without requiring separate delivery systems.
2Adaptability or versatility
If general opioid receptor antagonists are used, then both central and peripheral receptors are blocked, but this leads to unpredictable side effects and loss of analgesic efficacy
Solution Approach 1:
The amphipathic structure creates local quality differences in drug distribution. The lipophilic portion targets peripheral nerve membranes specifically, while the hydrophilic portion restricts the drug's ability to cross the blood-brain barrier. This spatial differentiation in drug action achieves selective peripheral receptor blockade without affecting central receptors, eliminating unpredictable side effects.
3Productivity
If conventional laxatives are used to treat opioid-induced constipation, then bowel movements are stimulated, but this often induces diarrhea and cramps with non-specific effects
Solution Approach 1:
The patent converts the harmful effect of opioid-induced constipation into a beneficial outcome by using the same opioid receptor antagonism mechanism that causes constipation when applied systemically. By making the antagonist amphipathic for selective peripheral action, the treatment resolves constipation through peripheral receptor blockade while avoiding the diarrhea and cramps associated with conventional laxatives, effectively converting a harmful side effect into a targeted therapeutic mechanism.
Data Source
Figure 1
AI summary
The present invention relates to an opioid receptor antagonist conjugate and a use thereof. In particular, the present invention relates to a covalent coupling conjugate of a hydrophilic polymer and an opioid receptor antagonist and the use thereof.